Omron launches one-touch home blood pressure monitor
BANNOCKBURN, Ill. Omron Healthcare on Monday launched the HEM-711DLX, a home blood pressure monitor designed to operate easily with quiet, one-touch operation.
HEM-711DLX features an expandable ComFit Cuff designed to fit both regular and large arms and employs IntelliSense technology to automatically determine the correct amount of pressure required to measure and generate an accurate reading.
Additionally, the monitor’s extra large digital display includes advanced diagnostic measures for hypertension, and detects irregular heartbeat in addition to standard metrics such as systolic and diastolic blood pressure, pulse, date and time.
“With the HEM-711DLX, monitoring blood pressure can become an easy habit to integrate into everyday living with the simplicity and comfort of this model’s features,” stated Shirley Huang, senior product manager, blood pressure for Omron.
The unit retails for a suggested $89.99.
Next, LaValle announce positive results from Seditol study
SALINAS, Calif. Next Pharmaceuticals and The LaValle Metabolic Institute last week announced the results of a clinical study on Seditol, concluding that the natural formulation provides relaxation, promotes restful sleep and helps reduce fatigue due to lack of sleep with minimal side effects.
“I believe that Seditol is a great alternative for people who are interested in a natural approach to managing sleeplessness,” stated Charles Kosmont, chief executive officer and president of Next Pharmaceuticals. “Exhausted Americans filled almost 50 million prescriptions for sleeping pills last year.”
The open-label, single-center trial of 773 people was completed by the LaValle Metabolic Institute in Cincinnati. Of those, 718 reported that Seditol helped them relax; 680 reported Seditol helped them have a restful night’s sleep; and 696 reported Seditol helped reduce fatigue due to lack of sleep.
Warburg Pincus completes B&L acquisition
ROCHESTER, N.Y. Bausch & Lomb and Warburg Pincus on Friday announced that Warburg Pincus has completed the acquisition of B&L for a total purchase price of approximately $4.5 billion, including the assumption of approximately $830 million in debt.
The company’s stock ceased trading on the New York Stock Exchange and was delisted by close of market Friday, the company announced.
“With a strong and supportive partner in Warburg Pincus, we are well-positioned to create new opportunities for Bausch & Lomb and advance our leadership in the eye health industry,” stated Ronald Zarrella, chairman and chief executive officer of B&L. “Our customers will continue to receive high levels of service, product quality and innovation, and our commitment to serving their needs remains steadfast.”